Search Result

Results for "

SARS-CoV-2 replication

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (91) Antibiotic (2) Apoptosis (2) Autophagy (2) Bacterial (2) Calcium Channel (2) Cathepsin (3) COX (2) Dengue Virus (2) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (2) DNA/RNA Synthesis (6) Flavivirus (3) HBV (4) HCV (7) HCV Protease (3) HIV (2) HSV (4) Influenza Virus (3) Isotope-Labeled Compounds (2) Ligands for Target Protein for PROTAC (1) Lipoxygenase (2) Mitophagy (2) NO Synthase (1) Parasite (3) PROTACs (2) Proteasome (1) Reverse Transcriptase (1) ROR (1) RSV (1) Sodium Channel (1) STING (1) Target Protein Ligand-Linker Conjugates (1) Toll-like Receptor (TLR) (1) Transketolase (1) Virus Protease (12)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (95) Inflammation/Immunology (5) Metabolic Disease (2)
Click Chemistry:	Azide (1) Alkynes (1)

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: SARS-CoV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162154

SARS-CoV-2-IN-75	SARS-CoV	Infection
SARS-CoV-2-IN-75 (compound 13) is a *SARS-CoV-2* inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC₆₈ (half-log reduction in viral titer) of 3 μM .

HY-168441

NCGC00537446	SARS-CoV	Infection
NCGC00537446 is a dual Nsp14 MTase/ExoN inhibitor. NCGC00537446 can be used for the research of SARS-CoV-2 replication and infection .

HY-161114

MDOLL-0229	SARS-CoV	Infection
MDOLL-0229 (compound 27) is an antiviral agent that targets SARS-CoV-2 Mac1 and repress coronavirus replication. MDOLL-0229 inhibits SARS-CoV-2 Mac1 with an IC₅₀ of 2.1 µM .

HY-131603

Lamivudine triphosphate 3TCTP	Reverse Transcriptase HCV HBV SARS-CoV	Infection
Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the Reverse Transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .

HY-157539

PB49673382	SARS-CoV	Infection
PB49673382 is a *SARS-CoV-2* inhibitor. PB49673382 inhibits virus replication and consequent cytopathic effects of the virus with an IC₅₀ of 6.42 μM .

HY-147020

Coronastat NK01-63	SARS-CoV	Infection
Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .

HY-160832

GC373	SARS-CoV	Infection
GC373 is a potent inhibitor of SARS-CoV-2 M_pro that blocks virus replication with an IC₅₀ of 0.4 μM. CG373 can be utilized in anti-COVID-19 research .

HY-105721

Aranotin	SARS-CoV	Infection
Aranotin strongly binds to Nsp15 viral protein. Aranotin can be used as promising **SARS-CoV-2 replication** strong inhibitor. Aranotin has the potential for COVID-19 research .

HY-144647

SP inhibitor 1	SARS-CoV Virus Protease	Infection
SP inhibitor 1 (compound 34) is a selective SARS-CoV-2 spike protein (SP) inhibitor with an IC₅₀ of 3.26 μM, >25 μM, >25 μM for SP, M ^pro and PL ^pro protein, respectively. SP inhibitor 1 is a vitro SARS-CoV-2 replication inhibitor at non-toxic concentrations (0.3250<5.98 μM). SP inhibitor 1 shows cellular antiviral activity .

HY-N144101

SARS-CoV MPro-IN-2	SARS-CoV	Infection
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M ^pro with an IC₅₀ value of 72.07 nM. The main protease (M ^pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .

HY-168600

SARS-CoV-2 Mpro-IN-32	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective inhibitor of SARS-CoV-2 M ^Pro with an IC₅₀ value of 230 nM. SARS-CoV-2 Mpro-IN-32 can also inhibit the replication of multiple *SARS-CoV-2* variants in vitro .

HY-139311

YH-53	SARS-CoV	Infection
YH-53 is a potent 3CL ^pro inhibitor with K_i values of 6.3 nM, 34.7 nM for SARS-CoV-1 3CL ^pro and SARS-CoV-2 3CL ^pro, respectively. YH-53 strongly blocks the SARS-CoV-2 replication. YH-53 is a peptidomimetic compound with a unique benzothiazolyl ketone. YH-53 has the potential for COVID-19 research .

HY-150783

SARS-CoV-2-IN-24	SARS-CoV	Infection
SARS-CoV-2-IN-24 (compound 7) is a potent papain-like protease (PL ^pro) inhibitor. SARS-CoV-2-IN-24 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. SARS-CoV-2-IN-24 can be used for SARS-CoV-2 research .

HY-149606

TKB245	SARS-CoV	Infection
TKB245 is a highly potent SARS-CoV-2 Mpro inhibitor that effectively blocks SARS-CoV-2 replication in VeroE6 cells .

HY-155015

SARS-CoV-2-IN-45	SARS-CoV	Infection
SARS-CoV-2-IN-45 (Compound 8p) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC₅₀ of 0.5 μM, and has no evident cytotoxic effect .

HY-144062

INSCoV-614(1B)	SARS-CoV	Infection
INSCoV-614(1B) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-151901

SARS-CoV-2 Mpro-IN-5	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-5 is a dual Inhibitor of Main Protease (M ^Pro) and Cathepsin L (CatL), with IC₅₀s of 1800 nM and 145 nM respectively. SARS-CoV-2 Mpro-IN-5 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-5 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC₅₀ value of 14.7 nM .

HY-151900

SARS-CoV-2 Mpro-IN-4	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-4 is a dual Inhibitor of Main Protease (M ^Pro) and Cathepsin L (CatL), with IC₅₀s of 900 nM and 60 nM respectively. SARS-CoV-2 Mpro-IN-4 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-4 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC₅₀ value of 8.2 nM .

HY-144260

3CPLro-IN-1	SARS-CoV	Infection
3CPLro-IN-1 (compound A17) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC₅₀ of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .

HY-W760546

SARS-CoV-2 3CLpro-IN-15	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .

HY-144063

INSCoV-600K(1)	SARS-CoV	Infection
INSCoV-600K(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-144061

INSCoV-601I(1)	SARS-CoV	Infection
INSCoV-601I(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-144263

3CPLro-IN-2	SARS-CoV	Infection
3CPLro-IN-2 (compound C1) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC₅₀ and K_i of 1.55 and 6.09 μM, respectively. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .

HY-158405

PAV-104	SARS-CoV	Infection
PAV-104 inhibits *SARS-CoV-2* replication, with the MOI of 0.01. PAV-104 can interact with *SARS-CoV-2* nucleocapsid (N) and interfered with its oligomerization, blocking particle assembly .

HY-145994

Obeldesivir ATV006	SARS-CoV	Infection
Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research .

HY-149868

SARS-CoV-2-IN-42	SARS-CoV	Infection
SARS-CoV-2-IN-42 (Compound 8q) is a potent inhibitor of *SARS-CoV-2* replication (EC₅₀: 0.4 μM). SARS-CoV-2-IN-42 has no obvious damage to the host cell .

HY-162151

SARS-CoV-2-IN-74	SARS-CoV	Infection
SARS-CoV-2-IN-74 (compound 30) is a epoxide inhibitor, which inhibits cellular SARS-CoV-2 replication with an EC₆₈ of 5 μM. SARS-CoV-2-IN-74 can be used for the research of coronavirus .

HY-150784

XR8-89	SARS-CoV	Infection
XR8-89 is a potent papain-like protease (PL ^pro) inhibitor with an IC₅₀ value of 0.1 μM. XR8-89 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. XR8-89 can be used for SARS-CoV-2 research .

HY-150786

PLP_Snyder530	SARS-CoV	Infection
PLP_Snyder530 is a potent papain-like protease (PL ^pro) inhibitor with an IC₅₀ value of 6.4 μM. PLP_Snyder530 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. PLP_Snyder530 can be used for SARS-CoV-2 research .

HY-169974

SARS-CoV-2-IN-107	SARS-CoV Virus Protease NO Synthase	Infection Inflammation/Immunology
SARS-CoV-2-IN-107 (Compound A7) is the inhibitor for SARS-CoV-2 3CLpro with an IC₅₀ of 261.3 nM. SARS-CoV-2-IN-107 inhibits the SARS-CoV-2 replication with an EC₅₀ of 11.7 μM. SARS-CoV-2-IN-107 exhibits anti-inflammatory activity with a NO inhibition rate of 68.6% in LPS (HY-D1056)-stimulated RAW264.7 macrophages .

HY-145277

SARS-CoV-2-IN-11	SARS-CoV	Infection
SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-145276

SARS-CoV-2-IN-10	SARS-CoV	Infection
SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-161777

SARS-CoV-2 Mpro-IN-23	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC₅₀ of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC₅₀ of 0.02-0.52 μM .

HY-156325

SARS-CoV-2-IN-62	SARS-CoV	Infection
SARS-CoV-2-IN-62 (Compound R3b) is an inhibitor of *SARS-CoV-2* replication and has low cytotoxicity. SARS-CoV-2-IN-62 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC₅₀ values of 2.97 μM and 3.82 μM, respectively .

HY-156337

SARS-CoV-2-IN-63	SARS-CoV	Infection
SARS-CoV-2-IN-63 (Compound R3e) is an inhibitor of *SARS-CoV-2* replication and has low cytotoxicity. SARS-CoV-2-IN-63 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC₅₀ values of 1.99 μM and 1.92 μM, respectively .

HY-109072

Riamilovir	SARS-CoV	Infection
Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of *SARS-CoV-2* .

HY-163067

SARS-CoV-2-IN-71	SARS-CoV	Infection
SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of *SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication* at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CL ^pro and TMPRSS2 .

HY-172437

Secutrelvir S-892216	Virus Protease SARS-CoV	Infection
Secutrelvir is the inhibitor for 3CL protease that exhibits antiviral activity through inhibition of SARS-CoV-2 replication .

HY-155014

SARS-CoV-2-IN-44	SARS-CoV	Infection
SARS-CoV-2-IN-44, a inhibitor of *SARS-CoV-2, inhibits viral replication, with an EC₅₀* of 0.6μM. SARS-CoV-2-IN-44 has no evident cytotoxic effect in Calu-3 cells and can be used for antiviral research .

HY-168455

RNAse L RIBOTAC	PROTACs	Infection
RNAse L RIBOTAC (compound C64) is an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. (Blue: RNA ligand (HY-168456); Black: linker (HY-130591); Pink: Rnase L ligand (HY-168457))

HY-164868

SARS-CoV-2-IN-106	SARS-CoV	Infection
SARS-CoV-2-IN-106 (compound 19) is a SARS-CoV-2 papain-like protease inhibitor with the IC₅₀ values of 0.44 μM and 0.18 μM for PLpro enzymatic and viral replication ,respectively .

HY-145435

SARS-CoV-2-IN-12	SARS-CoV	Infection
SARS-CoV-2-IN-12 (Compound 27) is a potent *SARS-CoV-2*-related 3C-like protease inhibitor (K_i=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19 .

HY-155016

SARS-CoV-2-IN-46	SARS-CoV	Infection
SARS-CoV-2-IN-46 is a novel coronavirus (SARS-CoV-2) replication inhibitor with an EC₅₀ of 0.9 μM in Calu-3 cells. SARS-CoV-2-IN-46 has antiviral activity and can be used in novel coronavirus (COVID-19) research .

HY-155527

SARS-CoV-2 Mpro-IN-9	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent *SARS-CoV-2* M ^pro inhibitor (IC₅₀=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC₅₀=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC₅₀>50 μM) .

HY-169419

SARS-CoV-2-IN-108	SARS-CoV Virus Protease	Infection
SARS-CoV-2-IN-108 (Compound 29) is an inhibitor for SARSCoV-2 papain-like protease with an IC₅₀ of 0.14 µM. SARS-CoV-2-IN-108 inhibits the virus replication with an EC₅₀ of 0.21 µM .

HY-149050

Viral polymerase-IN-1 hydrochloride	Influenza Virus SARS-CoV	Infection
Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC₉₀ values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against *SARS-CoV-2* infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .

HY-170309

NZ-804	SARS-CoV Virus Protease	Infection
NZ-804 is an orally active inhibitor for SARS-CoV-2 main protease Mpro with an IC₅₀ of 8.9 nM. NZ-804 inhibits the SARS-CoV-2 replication in HeLa-hACE2 cell with an EC₅₀ of 14 nM. NZ-804 exhibits board-spectrum antiviral activity aganst multiple CoVs. NZ-804 diminishes virus replication in mouse and hamster model .

HY-139165

AT-9010	SARS-CoV	Infection
AT-9010, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 can inhibit *SARS-CoV-2* replication .

HY-125729

Ivermectin B1b	Parasite SARS-CoV	Infection
Ivermectin B1b is the minor component of Ivermectin. Ivermectin, a potent anti-parasitic agent, inhibits the replication of SARS-CoV-2 in cell culture .

HY-169747

Benfooxythiamine	Transketolase SARS-CoV	Infection
Benfooxythiamine is a transketolase (TKT) inhibitor. Benfooxythiamine inhibits SARS-CoV-2 replication and increases the activity of the glycolysis inhibitor 2DG. Benfooxythiamine has antiviral activit .

Cat. No.	Product Name	Type

HY-B0961

Merbromin Mercury dibromofluorescein disodium salt; ZP1	Dyes
Merbromin is a mixed inhibitor of the 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2, with an IC₅₀ of 2.7 μM. Merbromin effectively inhibits the replication of the Zika virus (ZIKV) and shows anti-ZIKV activity by inhibiting ZIKVpro. Merbromin can also be used as a topical disinfectant for cuts and scrapes, and it serves as a biological dye .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-137984

Cnicin	Structural Classification Natural Products Source classification Centaurea benedicta (L.) L. Plants Compositae	SARS-CoV Apoptosis
Cnicin is an orally bioavailable sesquiterpene lactone. Cnicin has antibacterial and antiproliferative properties and induces apoptosis in primary myeloma cells. Cnicin also exhibits activity against *SARS-CoV-2. Cnicin inhibits the viral replication* of *SARS CoV-2* with an IC₅₀ of 1.18 μg/mL. Cnicin can promote functional nerve regeneration .

HY-13433

Thapsigargin Maximum Cited Publications 81 Publications Verification	Infection Classification of Application Fields Terpenoids Source classification Diterpenoids Umbelliferae Plants Disease Research Fields Thapsia garganica L. Cancer	Calcium Channel SARS-CoV Apoptosis
Thapsigargin, an endoplasmic reticulum (ER) stress inducer, is an inhibitor of microsomal Ca ²⁺-ATPase. Thapsigargin efficiently inhibits coronavirus (HCoV-229E, MERS-CoV, SARS-CoV-2) replication in different cell types .

HY-N1996

Chebulagic acid 4 Publications Verification	Structural Classification Classification of Application Fields Combretaceae Source classification Phenols Polyphenols Terminalia chebula Retz. Plants Inflammation/Immunology Disease Research Fields	COX Lipoxygenase SARS-CoV Influenza Virus
Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against *SARS-CoV-2* viral replication with an EC₅₀ of 9.76 μM.

HY-N0063

Punicalagin 5+ Cited Publications	Infection Structural Classification Punica granatum L. Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Punicaceae Plants Disease Research Fields	SARS-CoV HBV
Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CL ^pro inhibitor and inhibits *SARS-CoV-2* replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 .

HY-15310

Ivermectin 25+ Cited Publications MK-933; CD-5024; K-237	Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Antiviral Anti-parasitic Disease Research Disease Research Fields Cancer	Flavivirus Dengue Virus Parasite HIV Mitophagy HSV SARS-CoV Antibiotic Autophagy Bacterial
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against *SARS-CoV-2/COVID-19* .

HY-N144101

SARS-CoV MPro-IN-2	Infection Quinones Classification of Application Fields Source classification Plants Lithospermum canescens Lehm. Naphthalene Quinones Disease Research Fields Boraginaceae	SARS-CoV
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M ^pro with an IC₅₀ value of 72.07 nM. The main protease (M ^pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .

HY-N15365

Antcin B	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Virus Protease SARS-CoV
Antcin B is a SARS-CoV-2 3-chymotrypsin-like protease (3CL Pro) inhibitor. Antcin B binds to multiple key amino acid residues of 3CL Pro(such as Leu141, Asn142, Glu166, His163, etc.) through hydrogen bonds, salt bridges, and hydrophobic interactions, thereby inhibiting the activity of 3CL Pro, blocking the cleavage process of viral polyproteins, and suppressing the replication of the SARS-CoV-2 virus in host cells. Antcin B is promising for research of COVID-19 .

HY-N3445

Jaceidin triacetate	Sclerocarya birrea (A.Rich.) Hochst. Structural Classification Flavonoids Flavones Source classification Plants Anacardiaceae	SARS-CoV
Jaceidin triacetate(compound 54) is a natural compound isolated formmarulabark.Jaceidin triacetatecan inhibitSARS-CoV-2 Mpro, with theIC₅₀of 11.9μM.Jaceidin triacetateinhibits the replication of Sars-Cov-2 Viral in Vero-E6 cells .

HY-N1996R

Chebulagic acid (Standard)	Structural Classification Combretaceae Source classification Phenols Polyphenols Terminalia chebula Retz. Plants	COX Lipoxygenase SARS-CoV Influenza Virus
Chebulagic acid (Standard) is the analytical standard of Chebulagic acid. This product is intended for research and analytical applications. Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against SARS-CoV-2 viral replication with an EC₅₀ of 9.76 μM.

HY-N0063R

Punicalagin (Standard)	Structural Classification Punica granatum L. Source classification Phenols Polyphenols Punicaceae Plants	SARS-CoV HBV
Punicalagin (Standard) is the analytical standard of Punicalagin. This product is intended for research and analytical applications. Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CLpro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 .

HY-15310R

Ivermectin (Standard)	Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification Antiviral Anti-parasitic Disease Research	Dengue Virus Flavivirus Parasite HIV Mitophagy HSV SARS-CoV Antibiotic Autophagy Bacterial
Ivermectin (Standard) is the analytical standard of Ivermectin. This product is intended for research and analytical applications. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against *SARS-CoV-2/COVID-19* .

Cat. No.	Product Name	Chemical Structure

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-169220S

RORγ/DHODH-IN-1
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of *SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5)* .

Cat. No.	Product Name		Classification

HY-168458

RNA recruiter-linker 1		Alkynes
RNA recruiter-linker 1 is the RNA ligand-linker part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNA recruiter-linker 1 can be utilized in the synthesis of RIBOTAC .

HY-168457

RNase L ligand 2		Azide
RNase L ligand 2 (compound 6) is the Rnase L ligand part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNase L ligand 2 can be used in the synthesis of RIBOTAC .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks